Cost Effectiveness of Perioperative Durvalumab Plus Neoadjuvant Chemotherapy for Muscle Invasive Bladder Cancer in the United States
Research Summary: Muscle invasive bladder cancer (MIBC) is an aggressive subtype of bladder cancer that
Research Summary: Muscle invasive bladder cancer (MIBC) is an aggressive subtype of bladder cancer that
Research Summary: KRAS G12C mutations occur in a substantial subset of advanced non-small cell lung
Research Summary: Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are B-cell malignancies that
Research Summary: Capivasertib is a potent, selective inhibitor of all three protein kinase B (AKT1/2/3)
Research Summary: Covalent Bruton tyrosine kinase (BTK) inhibitors have become the preferred treatment for chronic
Research Summary: Accurate prognostic assessment in patients with cutaneous melanoma is essential as it is
Research Summary: Cutaneous melanoma is a significant public health concern, as it is the fifth
Research Summary: Estrogen receptor–positive (ER+) breast cancer is primarily driven by signaling through estrogen receptor
Research Summary: Ciltacabtagene autoleucel (cilta-cel) is a B-cell maturation antigen (BCMA)–targeted chimeric antigen receptor T-cell
Research Summary: The EMBER-3 trial1 was a Phase III, open-label study that evaluated imlunestrant, a
Research Summary: For patients with heavily pretreated relapsed/refractory multiple myeloma (RRMM), prior reports have shown
Research Summary Chimeric antigen receptor T-cell (CAR-T) therapy is typically administered in the inpatient setting,
Research Summary This study1 evaluated the Medicare cost impact of choosing among covalent Bruton tyrosine
Research Summary In this randomized, controlled, Phase III study,1 patients with resectable, epidermal growth factor
Research Summary Advances in T-cell redirecting therapy (TCRT), which includes chimeric antigen receptor T-cell (CAR-T)
Research Summary Ciltacabtagene autoleucel (cilta-cel) is a second-generation autologous chimeric antigen receptor T-cell (CAR-T) therapy
This study examines how the FOXO3–FOXM1 regulatory axis influences sensitivity to AKT inhibition in PIK3CA- and PIK3CA/PTEN-altered estrogen receptor–positive breast cancer.
Results from a meta-analysis evaluate the efficacy and safety of acalabrutinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia.
Findings from a multicenter study evaluate whether adding durvalumab after chemoradiotherapy improves survival outcomes in patients with KRAS-mutated Stage III non-small cell lung cancer.
This review outlines the role of oncology nurses in managing patients with multiple myeloma throughout the chimeric antigen receptor T-cell therapy process.
©2026 Oncology Matrix. All Rights Reserved.